Earnings ·
Roivant Sciences Ltd. reported financial results for the first quarter ended June 30, 2026, on August 6, 2026
ROIVRoivant Sciences Ltd.
Roivant Sciences Ltd. reported financial results for the first quarter ended June 30, 2026, on August 6, 2026. The company posted a net loss of $189.8 million, or $0.26 per share, compared to a net loss of $223.4 million in the prior year period. R&D expenses rose to $202.0 million and G&A expenses increased to $165.5 million, largely driven by bonuses related to a global patent infringement settlement with Moderna. Roivant recognized a gain on litigation settlement of $392 thousand. The company held $3.9 billion in cash and marketable securities as of June 30, 2026. During the quarter, Roivant repurchased 7.3 million common shares for approximately $208.7 million. Commercial preparations for brepocitinib in dermatomyositis are on track for a September 2026 launch, with first patients enrolled in a Phase 3 study for cutaneous sarcoidosis. Roivant Sciences Ltd. is a biopharmaceutical company that develops and commercializes medicines through specialized subsidiaries.